Literature DB >> 33505737

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia.

Di Wu1, Wenlan Chen1, Zhichao Chen1, Qiubai Li1.   

Abstract

Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using venetoclax combined with hypomethylating agents, which successfully induced complete remission with tolerable toxicities.
Copyright © 2021 Di Wu et al.

Entities:  

Year:  2021        PMID： 33505737      PMCID： PMC7815380          DOI： 10.1155/2021/6661109

Source DB:  PubMed          Journal:  Case Rep Hematol        ISSN： 2090-6579


  18 in total

1.  Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.

Authors:  Christopher B Benton; Deborah A Thomas; Hui Yang; Farhad Ravandi; Michael Rytting; Susan O'Brien; Anna R Franklin; Gautam Borthakur; Samuel Dara; Monica Kwari; Sherry R Pierce; Elias Jabbour; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

2.  Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.

Authors:  Xiaoxia Wu; Jian Zhang; Qiwei Chen; Lili Zhou; Mengyun Li; Huiying Qiu; Aining Sun; Depei Wu
Journal:  Br J Haematol       Date:  2020-04-03       Impact factor: 6.998

3.  Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Martin S Tallman; Eunice S Wang; Jessica K Altman; Frederick R Appelbaum; Vijaya Raj Bhatt; Dale Bixby; Steven E Coutre; Marcos De Lima; Amir T Fathi; Melanie Fiorella; James M Foran; Aric C Hall; Meagan Jacoby; Jeffrey Lancet; Thomas W LeBlanc; Gabriel Mannis; Guido Marcucci; Michael G Martin; Alice Mims; Margaret R O'Donnell; Rebecca Olin; Deniz Peker; Alexander Perl; Daniel A Pollyea; Keith Pratz; Thomas Prebet; Farhad Ravandi; Paul J Shami; Richard M Stone; Stephen A Strickland; Matthew Wieduwilt; Kristina M Gregory; Lydia Hammond; Ndiya Ogba
Journal:  J Natl Compr Canc Netw       Date:  2019-06-01       Impact factor: 11.908

4.  Survival of patients with mixed phenotype acute leukemias: A large population-based study.

Authors:  Runhua Shi; Reinhold Munker
Journal:  Leuk Res       Date:  2015-03-28       Impact factor: 3.156

Review 5.  Optimal therapeutic strategies for mixed phenotype acute leukemia.

Authors:  Ofir Wolach; Richard M Stone
Journal:  Curr Opin Hematol       Date:  2020-03       Impact factor: 3.284

6.  Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population.

Authors:  Xiao-Qian Xu; Jian-Min Wang; Shu-Qing Lü; Li Chen; Jian-Min Yang; Wei-Ping Zhang; Xian-Min Song; Jun Hou; Xiong Ni; Hui-Ying Qiu
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

Review 7.  The rise of apoptosis: targeting apoptosis in hematologic malignancies.

Authors:  Rebecca Valentin; Stephanie Grabow; Matthew S Davids
Journal:  Blood       Date:  2018-07-16       Impact factor: 22.113

8.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

9.  Mixed-phenotype acute leukemia treated with decitabine.

Authors:  Ji-Young Lee; Sang-Min Lee; Ja-Young Lee; Ki-Hyang Kim; Moon-Young Choi; Won-Sik Lee
Journal:  Korean J Intern Med       Date:  2016-02-15       Impact factor: 2.884

10.  Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.

Authors:  Koichi Takahashi; Feng Wang; Kiyomi Morita; Yuanqing Yan; Peter Hu; Pei Zhao; Abdallah Abou Zhar; Chang Jiun Wu; Curtis Gumbs; Latasha Little; Samantha Tippen; Rebecca Thornton; Marcus Coyle; Marisela Mendoza; Erika Thompson; Jianhua Zhang; Courtney D DiNardo; Nitin Jain; Farhad Ravandi; Jorge E Cortes; Guillermo Garcia-Manero; Steven Kornblau; Michael Andreeff; Elias Jabbour; Carlos Bueso-Ramos; Akifumi Takaori-Kondo; Marina Konopleva; Keyur Patel; Hagop Kantarjian; P Andrew Futreal
Journal:  Nat Commun       Date:  2018-07-10       Impact factor: 14.919
View more
  3 in total

Review 1.  Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?

Authors:  Marie C Béné; Anna Porwit
Journal:  Curr Oncol Rep       Date:  2022-04-05       Impact factor: 5.945

2.  Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia.

Authors:  Nathan P Horvat; Constantine N Logothetis; Ling Zhang; Seongseok Yun; Kendra Sweet
Journal:  Cureus       Date:  2022-03-29

Review 3.  Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies.

Authors:  Binsah S George; Binoy Yohannan; Anneliese Gonzalez; Adan Rios
Journal:  Biomedicines       Date:  2022-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.